Paloma Partners Management Co Has $1.53 Million Stock Position in Catalent, Inc. (NYSE:CTLT)

Paloma Partners Management Co raised its holdings in Catalent, Inc. (NYSE:CTLT) by 345.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 25,179 shares of the company’s stock after buying an additional 19,523 shares during the quarter. Paloma Partners Management Co’s holdings in Catalent were worth $1,525,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Brooklyn Investment Group bought a new stake in shares of Catalent in the 3rd quarter valued at $31,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Catalent in the second quarter valued at $42,000. Sentry Investment Management LLC acquired a new position in shares of Catalent during the third quarter valued at about $53,000. Longfellow Investment Management Co. LLC boosted its position in shares of Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after purchasing an additional 305 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after buying an additional 212 shares during the period.

Analysts Set New Price Targets

Several brokerages have issued reports on CTLT. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. StockNews.com upgraded shares of Catalent from a “sell” rating to a “hold” rating in a report on Monday. Finally, William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Eight analysts have rated the stock with a hold rating, Based on data from MarketBeat, Catalent presently has an average rating of “Hold” and an average price target of $63.40.

Insider Buying and Selling

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,114 shares of company stock worth $305,931. 0.31% of the stock is owned by company insiders.

Catalent Stock Performance

NYSE CTLT opened at $61.45 on Tuesday. The company has a fifty day moving average price of $59.93 and a 200-day moving average price of $58.55. The firm has a market cap of $11.15 billion, a price-to-earnings ratio of -27.19, a PEG ratio of 2.43 and a beta of 1.16. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. Catalent, Inc. has a 1 year low of $36.74 and a 1 year high of $61.50.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the company posted ($0.10) earnings per share. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. As a group, equities research analysts predict that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.